CompaniesAstraZeneca Seeks US Authorization for COVID-19 Preventive TreatmentSaveMark Us Preferred on GooglePrintThe logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Del., on March 22, 2021. Rachel Wisniewski/ReutersZachary StieberSenior Reporter10/5/2021|Updated: 10/5/2021A European biotechnology firm on Tuesday announced it’s seeking emergency authorization of a treatment it says can prevent symptomatic COVID-19.AstraZeneca said it submitted an emergency use authorization (EUA) request for an antibody combination drug dubbed AZD7442.We had a problem loading this article. Please enable javascript or use a different browser. If the issue persists, please visit our help center.
